ET
The startup has developed an exosome-based platform that utilizes proprietary vesicles with regenerative, anti-inflammatory, and immunomodulatory properties to create therapeutic products. This technology provides healthcare providers with targeted treatment options for skin and autoimmune diseases.
Updated 18 months ago
Funding
$980K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EFunding rounds are not available yet.
Founders
Product
Features
- The startup has developed an exosome-based platform that utilizes proprietary vesicles with regenerative, anti-inflammatory, and immunomodulatory properties to create therapeutic products. This technology provides healthcare providers with targeted treatment options for skin and autoimmune diseases.